Compare GSK plc (GSK) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sirius XM Holdings Inc — how do they compare? GSK plc trades at $52.76 (market cap $101.34B), while Sirius XM Holdings Inc trades at $31.18 (market cap $10.32B). The key difference: GSK plc is far larger — about 9.8× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| GSK | SIRI | |
|---|---|---|
Market Cap | $101.34B | $10.32B |
Sector | Health | Media |
52-Week High | $61.18 | $30.75 |
52-Week Low | $36.20 | $19.92 |
Enterprise Value | $121.95B | $19.99B |
Dividend Yield | 3.49% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Sirius XM Holdings (SIRI) trades at $31.16, up 2.53% today, with a bullish technical outlook supported by moving averages. The stock shows solid fundamentals with a P/E of 12.99, P/B of 0.88, and net income margin of 9.86%. Recent Q1 2026 earnings beat expectations, and the company announced a $0.27 dividend for H1 2026. Positive sentiment is driven by a new YouTube ad partnership and inclusion in the S&P MidCap 400 index as of June 2026.
The outlook is positive with analyst consensus favoring Buy (58% of ratings) and a $31.17 price target. Key opportunities include revenue growth from digital advertising and strong cash flow. Risks involve competitive pressures in media and high debt levels. The stock remains attractive for value and income investors, though monitoring Q2 2026 earnings on July 30, 2026, is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
